R. Fruchtmann

Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 {(R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid} and structurally related compounds

Armin Hatzelmann, R. Fruchtmann, Klaus Mohrs et al. · Biochemical Pharmacology · 1993 · 78 citations

Medicinal Chemistry, Heterocyclic, Biochemistry +7

In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis

R. Fruchtmann, Klaus Mohrs, Armin Hatzelmann et al. · Inflammation Research · 1993 · 47 citations

Molecular Pharmacology, Bay X1005, Medicine +8

BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics.

R. Müller‐Peddinghaus, C. Kohlsdorfer, Pia Theisen-Popp et al. · Journal of Pharmacology and Experimental Therapeutics · 1993 · 39 citations

Inversely-correlated inhibition of human 5-lipoxygenase activity by bay X1005 and other quinoline derivatives in intact cells and a cell-free system—implications for the function of 5-lipoxygenase activating protein

Armin Hatzelmann, J. Goossens, R. Fruchtmann et al. · Biochemical Pharmacology · 1994 · 25 citations

Redox Signaling, Molecular Pharmacology, Biochemistry +12

The antipsoriatic drug, anthralin, inhibits protein kinase C — implications for its mechanism of action

L. Hegemann, R. Fruchtmann, Lucio A.A. Van Rooijen et al. · Archives of Dermatological Research · 1992 · 22 citations

Molecular Pharmacology, Signal Transduction, Medicine +8